<DOC>
	<DOC>NCT00860353</DOC>
	<brief_summary>The purpose of this study is to determine how well tolerated and safe AZD2551 is at different dose levels in healthy, non-smoking males. It will also investigate how quickly AZD2551 is absorbed into and cleared by the body</brief_summary>
	<brief_title>Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551</brief_title>
	<detailed_description />
	<criteria>Provision of signed, written and dated informed consent prior to any study specific procedures Be willing to use barrier methods of contraception unless their partners are postmenopausal, surgically sterile or using accepted contraceptive methods Have a body mass index between 18 and 30 kg/m2 inclusive and weight at least 50kg and no more than 100kg Use of any prescribed or nonprescribed medication during the two weeks prior to the administration of study drug History or presence of conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs Any impairment of kidney function or laboratory results for markers of kidney function that are outside the reference range and considered clinically significant Underlying musculoskeletal symptoms of unknown origin, subjects with shoulder girdle musculoskeletal symptoms or Dupuytrens syndrome</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Healthy Volunteer</keyword>
	<keyword>Single Ascending Dose</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>AZD2551</keyword>
	<keyword>Healthy Volunteer Study</keyword>
</DOC>